Fig. 7

Antitumor therapeutic efficacy of on CT26 tumor in vivo. A Treatment schedule for Fe-PHCN@DOX and anti-PD-L1 nanobody (Nab) combination therapy. Tumor growth curves (B) and inhibition rates (C) from various groups, including a) PBS; b) Fe-PHCN; c) Fe-PHCN@DOX; d) Fe-PHCN@DOX plus laser; and e) Fe-PHCN@DOX plus laser plus anti-PD-L1 nanobody. Tumor weights (D) and representative photos of tumor size (E) of mice in each group. Survival rates (F) and body weights (G) of mice after different treatments. H Fluorescence images of TUNEL-stained tumor slices after various treatments. Cell nuclei were stained with DAPI (blue fluorescence). Green fluorescence indicates TUNEL-positive cells. I H&E-stained images of tumor slices obtained from different groups of mice. The scale bar represents 100 μm. The p values were analyzed using the Log-rank (Mantel-Cox) test. Data are presented as the mean ± standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001